These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26605908)

  • 1. Comparison between Fondaparinux and Low-Molecular-Weight Heparin in Patients with Acute Coronary Syndrome: A Meta-Analysis.
    Qiao J; Zhang X; Zhang J; Li P; Xu B; Wang S; Jiang H; Shen Y; Wang K
    Cardiology; 2016; 133(3):163-72. PubMed ID: 26605908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor Xa inhibitors for acute coronary syndromes.
    Brito V; Ciapponi A; Kwong J
    Cochrane Database Syst Rev; 2011 Jan; (1):CD007038. PubMed ID: 21249686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: A meta-analysis.
    Mu F; Wang M; Huang J; Wang F
    Eur J Obstet Gynecol Reprod Biol; 2023 Aug; 287():29-35. PubMed ID: 37276726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.
    Szummer K; Oldgren J; Lindhagen L; Carrero JJ; Evans M; Spaak J; Edfors R; Jacobson SH; Andell P; Wallentin L; Jernberg T
    JAMA; 2015 Feb; 313(7):707-16. PubMed ID: 25688782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of therapeutic efficacy between fondaparinux and low molecular weight heparin for patients with acute coronary syndrome].
    Wang QK; Guo M; Zhang YQ; Song Y
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Oct; 22(10):628-31. PubMed ID: 20977850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
    Puymirat E; Schiele F; Ennezat PV; Coste P; Collet JP; Bonnefoy-Cudraz E; Roul G; Richard P; Simon T; Danchin N
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):211-9. PubMed ID: 25075006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.
    Bundhun PK; Shaik M; Yuan J
    BMC Cardiovasc Disord; 2017 May; 17(1):116. PubMed ID: 28482804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
    Budaj A; Eikelboom JW; Mehta SR; Afzal R; Chrolavicius S; Bassand JP; Fox KA; Wallentin L; Peters RJ; Granger CB; Joyner CD; Yusuf S;
    Eur Heart J; 2009 Mar; 30(6):655-61. PubMed ID: 18713759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of un-fractionated heparin and low molecular weight heparin on hospital mortality in patients with non ST elevation acute coronary syndrome (ACS).
    Angkasuwapala K; Ratanasumawong K; Ngarmukos T; Kehasukcharoen W; Boonsom W; Kamsa-ard S
    J Med Assoc Thai; 2007 Oct; 90 Suppl 1():109-14. PubMed ID: 18431893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
    ; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA
    N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of acute coronary syndromes with fondaparinux.
    Wienbergen H; Zeymer U
    Vasc Health Risk Manag; 2007; 3(3):321-9. PubMed ID: 17703640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fondaparinux in acute coronary syndromes.
    Chaturvedi V; Karthikeyan G
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1615-23. PubMed ID: 19929450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
    Joyner CD; Peters RJ; Afzal R; Chrolavicius S; Mehta SR; Fox KA; Granger CB; Franzosi MG; Flather M; Budaj A; Bassand JP; Yusuf S
    Am Heart J; 2009 Mar; 157(3):502-8. PubMed ID: 19249421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fondaparinux in patients with acute coronary syndromes.
    Bassand JP; Richard-Lordereau I; Cadroy Y
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1013-26. PubMed ID: 18035917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.